VAREX IMAGING CORP (VREX) Fundamental Analysis & Valuation

NASDAQ:VREX • US92214X1063

10.81 USD
-0.05 (-0.46%)
At close: Mar 13, 2026
11.14 USD
+0.33 (+3.05%)
After Hours: 3/13/2026, 8:02:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VREX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

VREX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of VREX while its profitability can be described as average. VREX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. VREX Profitability Analysis

1.1 Basic Checks

  • In the past year VREX was profitable.
  • VREX had a positive operating cash flow in the past year.
  • In multiple years VREX reported negative net income over the last 5 years.
  • Each year in the past 5 years VREX had a positive operating cash flow.
VREX Yearly Net Income VS EBIT VS OCF VS FCFVREX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

1.2 Ratios

  • The Return On Assets of VREX (-6.17%) is better than 66.30% of its industry peers.
  • VREX has a better Return On Equity (-14.20%) than 64.13% of its industry peers.
  • VREX has a Return On Invested Capital of 5.94%. This is in the better half of the industry: VREX outperforms 78.80% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for VREX is below the industry average of 9.18%.
  • The last Return On Invested Capital (5.94%) for VREX is above the 3 year average (4.82%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -6.17%
ROE -14.2%
ROIC 5.94%
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
VREX Yearly ROA, ROE, ROICVREX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • The Operating Margin of VREX (8.23%) is better than 74.46% of its industry peers.
  • In the last couple of years the Operating Margin of VREX has declined.
  • VREX has a Gross Margin of 34.15%. This is in the lower half of the industry: VREX underperforms 73.91% of its industry peers.
  • VREX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.23%
PM (TTM) N/A
GM 34.15%
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
VREX Yearly Profit, Operating, Gross MarginsVREX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VREX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), VREX is destroying value.
  • VREX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for VREX has been increased compared to 5 years ago.
  • The debt/assets ratio for VREX has been reduced compared to a year ago.
VREX Yearly Shares OutstandingVREX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
VREX Yearly Total Debt VS Total AssetsVREX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • VREX has an Altman-Z score of 1.94. This is not the best score and indicates that VREX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • VREX has a Altman-Z score (1.94) which is in line with its industry peers.
  • VREX has a Debt/Equity ratio of 0.78. This is a neutral value indicating VREX is somewhat dependend on debt financing.
  • The Debt to Equity ratio of VREX (0.78) is worse than 69.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 1.94
ROIC/WACC0.58
WACC10.29%
VREX Yearly LT Debt VS Equity VS FCFVREX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 3.89 indicates that VREX has no problem at all paying its short term obligations.
  • VREX has a better Current ratio (3.89) than 64.67% of its industry peers.
  • A Quick Ratio of 1.87 indicates that VREX should not have too much problems paying its short term obligations.
  • The Quick ratio of VREX (1.87) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 1.87
VREX Yearly Current Assets VS Current LiabilitesVREX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. VREX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 78.57% over the past year.
  • The Earnings Per Share has been growing by 57.78% on average over the past years. This is a very strong growth
  • Looking at the last year, VREX shows a small growth in Revenue. The Revenue has grown by 4.09% in the last year.
  • Measured over the past years, VREX shows a small growth in Revenue. The Revenue has been growing by 2.73% on average per year.
EPS 1Y (TTM)78.57%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%171.43%
Revenue 1Y (TTM)4.09%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%4.9%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.31% on average over the next years. This is quite good.
  • Based on estimates for the next years, VREX will show a small growth in Revenue. The Revenue will grow by 5.15% on average per year.
EPS Next Y3.8%
EPS Next 2Y8.68%
EPS Next 3Y14.64%
EPS Next 5Y18.31%
Revenue Next Year4.48%
Revenue Next 2Y4.18%
Revenue Next 3Y4.62%
Revenue Next 5Y5.15%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VREX Yearly Revenue VS EstimatesVREX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
VREX Yearly EPS VS EstimatesVREX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

5

4. VREX Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 10.81, the valuation of VREX can be described as very reasonable.
  • Based on the Price/Earnings ratio, VREX is valued cheaper than 91.85% of the companies in the same industry.
  • VREX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.70.
  • A Price/Forward Earnings ratio of 10.40 indicates a reasonable valuation of VREX.
  • VREX's Price/Forward Earnings ratio is rather cheap when compared to the industry. VREX is cheaper than 94.02% of the companies in the same industry.
  • VREX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.84.
Industry RankSector Rank
PE 10.81
Fwd PE 10.4
VREX Price Earnings VS Forward Price EarningsVREX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, VREX is valued cheaply inside the industry as 96.20% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.17
VREX Per share dataVREX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • VREX's earnings are expected to grow with 14.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.85
PEG (5Y)0.19
EPS Next 2Y8.68%
EPS Next 3Y14.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VREX Dividend Analysis

5.1 Amount

  • No dividends for VREX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VREX Fundamentals: All Metrics, Ratios and Statistics

VAREX IMAGING CORP

NASDAQ:VREX (3/13/2026, 8:02:40 PM)

After market: 11.14 +0.33 (+3.05%)

10.81

-0.05 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners98.54%
Inst Owner Change3.93%
Ins Owners1.58%
Ins Owner Change15.69%
Market Cap452.94M
Revenue(TTM)854.40M
Net Income(TTM)-67.70M
Analysts83.64
Price Target19.18 (77.43%)
Short Float %3.01%
Short Ratio3.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.41%
Min EPS beat(2)40.06%
Max EPS beat(2)98.76%
EPS beat(4)4
Avg EPS beat(4)156.06%
Min EPS beat(4)40.06%
Max EPS beat(4)404.2%
EPS beat(8)6
Avg EPS beat(8)96.39%
EPS beat(12)9
Avg EPS beat(12)67.16%
EPS beat(16)13
Avg EPS beat(16)58.24%
Revenue beat(2)1
Avg Revenue beat(2)0.64%
Min Revenue beat(2)-1.06%
Max Revenue beat(2)2.35%
Revenue beat(4)3
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-1.06%
Max Revenue beat(4)4.57%
Revenue beat(8)4
Avg Revenue beat(8)0.23%
Revenue beat(12)5
Avg Revenue beat(12)0.05%
Revenue beat(16)8
Avg Revenue beat(16)0.29%
PT rev (1m)6.21%
PT rev (3m)9.3%
EPS NQ rev (1m)4.88%
EPS NQ rev (3m)4.88%
EPS NY rev (1m)5.14%
EPS NY rev (3m)4.13%
Revenue NQ rev (1m)1.11%
Revenue NQ rev (3m)1.11%
Revenue NY rev (1m)0.54%
Revenue NY rev (3m)0.54%
Valuation
Industry RankSector Rank
PE 10.81
Fwd PE 10.4
P/S 0.53
P/FCF N/A
P/OCF 28.13
P/B 0.95
P/tB 1.72
EV/EBITDA 7.17
EPS(TTM)1
EY9.25%
EPS(NY)1.04
Fwd EY9.61%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)0.38
OCFY3.55%
SpS20.39
BVpS11.38
TBVpS6.3
PEG (NY)2.85
PEG (5Y)0.19
Graham Number16
Profitability
Industry RankSector Rank
ROA -6.17%
ROE -14.2%
ROCE 7.52%
ROIC 5.94%
ROICexc 6.86%
ROICexgc 9.31%
OM 8.23%
PM (TTM) N/A
GM 34.15%
FCFM N/A
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
ROICexc(3y)5.86%
ROICexc(5y)6.54%
ROICexgc(3y)8.71%
ROICexgc(5y)10.09%
ROCE(3y)6.1%
ROCE(5y)7.01%
ROICexgc growth 3Y-6.75%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.38%
ROICexc growth 5YN/A
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA 3.82
Cap/Depr 109.29%
Cap/Sales 3.44%
Interest Coverage 2.18
Cash Conversion 16.56%
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 1.87
Altman-Z 1.94
F-Score5
WACC10.29%
ROIC/WACC0.58
Cap/Depr(3y)77.68%
Cap/Depr(5y)67.38%
Cap/Sales(3y)2.78%
Cap/Sales(5y)2.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.57%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%171.43%
EPS Next Y3.8%
EPS Next 2Y8.68%
EPS Next 3Y14.64%
EPS Next 5Y18.31%
Revenue 1Y (TTM)4.09%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%4.9%
Revenue Next Year4.48%
Revenue Next 2Y4.18%
Revenue Next 3Y4.62%
Revenue Next 5Y5.15%
EBIT growth 1Y79.34%
EBIT growth 3Y-8.72%
EBIT growth 5YN/A
EBIT Next Year53.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-113.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.85%
OCF growth 3Y35.13%
OCF growth 5Y25.87%

VAREX IMAGING CORP / VREX FAQ

What is the fundamental rating for VREX stock?

ChartMill assigns a fundamental rating of 4 / 10 to VREX.


What is the valuation status of VAREX IMAGING CORP (VREX) stock?

ChartMill assigns a valuation rating of 5 / 10 to VAREX IMAGING CORP (VREX). This can be considered as Fairly Valued.


What is the profitability of VREX stock?

VAREX IMAGING CORP (VREX) has a profitability rating of 5 / 10.


How financially healthy is VAREX IMAGING CORP?

The financial health rating of VAREX IMAGING CORP (VREX) is 3 / 10.


What is the expected EPS growth for VAREX IMAGING CORP (VREX) stock?

The Earnings per Share (EPS) of VAREX IMAGING CORP (VREX) is expected to grow by 3.8% in the next year.